Neat Stich, an automated Port Closure.
NeatStich is a medical device company focused on development of innovative port closure solutions. NeatStitch is the creator of NeatCloseTM, the first automated port closure device for laparoscopic surgery
3D video clip produced by Virtual Point Multimedia

Cataract Surgery Medical Eye Video

Laparoscopic Gastric Banding in Qatar by Dr. Emadi

LASIK Eye Surgery 3D Animation

Laparoscopy in Hemodynamic Instable Patient

Pediatric Neurological Examination

Drugs Through a Saline Lock

Kidney and Nephron

Abnormal Eye Lid Positions Ptosis

A simple video showing the small tips to be followed by patients which a clinician should provide. The video is simple, easy to understand and can be provided to the patient for their reference.

Prosthetic Aortic Valve Replacement Surgery 3D

most innovative immediate dental implant system

IBS Symptoms and treatment video

Crohns Disease Patient Education

Diverticulitis Attack Surgery

http://www.landging.com/nervous-system-animation.html Human body nervous system, 3D MOA (Mechanism of Action) animation, designed for Beijing Natural History Museum.

http://www.landging.com/skeletal-system-animation-aci-surgery.html
Designed for medical research organization, this skeletal system animation demonstrates the new concept of ACI (autologous chondrocyte implantation) surgery procedure.

Toilet Phobia Cure Bathroom Anxiety Phobia Of Public Toilets, Paruresis Shy Bladder.
http://paruresistreatment.plus101.com .

Shy bladder syndrome is a type of phobia in which the sufferers are unable to urinate in the presence of other people such as in a public restroom.

In other words, shy bladder is the fear of not being able to urinate without complete privacy.

How common is paruresis?

While there is no way for certain to know how many people suffer from paruresis, surveys done over the last several decades indicate that the numbers could range from less than one percent to more than 25 percent of Americans.

there is a new solution for those people who want to learn to overcome their shy bladder within a few weeks. Click Here to Learn More! http://paruresistreatment.plus101.com

Subscribe to Our Channel

http://www.youtube.com/watch?v=aVrTVCKrfC0
Toilet Phobia Cure, Bathroom Anxiety, Phobia Of Public Toilets, Paruresis Shy Bladder,
Treatment System
bashful bladder
bashful kidneys
bladder shyness
bladder shyness men
bladder shyness women
creeping pee pee
getting over stage fright
how to get rid of a phobia
how to stop stage fright
mental cloggery
overcoming stage fright
pee fright
pee shyness
public piss syndrome
shy bladder syndrom
shy bladder syndrome
stage fright
the slow dribbles
urophobia
Overcome Shy Bladder
How To Overcome Shy Bladder
can t urinate
pauresis

https://www.youtube.com/watch?v=0N7Yy1UYEWk

Renal transplantation is the treatment of choice for a minority of patients with end-stage renal disease (ESRD). Most adult patients with ESRD are never referred for evaluation for transplantation, and have a 70% 5-year mortality on dialysis. Marked improvements in early graft survival and long-term graft function have made kidney transplantation a more cost-effective alternative to dialysis. In the United States, over 375,000 kidney transplants have been performed, and in 2012, 191,400 patients were alive and with a functioning transplanted kidney; currently, more than 101,000 patients are waiting for kidney transplants.[1, 2] Before the advent of immunosuppression, renal transplantation was limited to identical twins and was not applicable to the vast majority of patients with ESRD. The introduction of combined azathioprine-steroid therapy in 1963 produced encouraging results and became the mainstay of immunosuppression. Although this therapy improved the results of transplantation, acute rejection and complications associated with steroid therapy persisted. The introduction of cyclosporine in 1983 significantly improved the outcomes of all solid-organ transplants by reducing the risk of rejection. Further innovations, including anti–T cell antibodies (both monoclonal and polyclonal preparations), as well as other maintenance immunosuppressants (eg, tacrolimus, mycophenolate, sirolimus), have made a significant impact on both patient and graft survival. Currently, 1-year patient and graft survival rates exceed 90% in most transplant centers. For patient education information, see Kidney Transplant and the Mayo Clinic's kidney transplant information Web page.